ML365 inhibits lipopolysaccharide-induced inflammatory responses via the NF-κB signaling pathway

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• ML365 is a selective inhibitor of the TWIK-related acid-sensitive potassium channel 1 (TASK1).
• No prior studies investigated ML365's role in inflammation inhibition.
• Lipopolysaccharide (LPS) is a potent inducer of inflammatory responses.

Purpose of the Study:

• To evaluate the anti-inflammatory effects of ML365 on LPS-induced inflammation.
• To elucidate the underlying molecular mechanisms of ML365's anti-inflammatory action.

Main Methods:

• In vitro studies using RAW264.7 cells to assess cytotoxicity, apoptosis, nitric oxide production, and cytokine release (TNF-α, IL-6, IL-1β).
• Analysis of NF-κB pathway activation, including nuclear translocation and co-localization.
• Western blot analysis to determine the expression of key inflammatory kinases (Erk, p38, Jnk).
• In vivo studies using an LPS-induced endotoxin shock model in mice.

Main Results:

• ML365 exhibited no cytotoxicity or apoptosis induction in RAW264.7 cells.
• ML365 significantly inhibited nitric oxide production and the release of TNF-α, IL-6, and IL-1β.
• ML365 suppressed LPS-induced NF-κB activation and the phosphorylation of Erk, p38, and Jnk.
• In vivo, ML365 mitigated pathological damage in the LPS-induced endotoxin shock model.

Conclusions:

• ML365 possesses significant anti-inflammatory properties against LPS-induced inflammation.
• The anti-inflammatory mechanism involves the regulation of the NF-κB signaling pathway.
• ML365 demonstrates therapeutic potential for inflammatory conditions.